Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin,…

By J. Tabernero, T. Yoshino, A. Cohn, R. Obermannova, G. Bodoky, R. García-Carbonero, T. Ciuleanu, D. Portnoy, E. Van Cutsem, A. Grothey and 9 more. The Lancet Oncology, 2015

797 citations recorded by the source corpus.

Subfields: Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/b21b77ffb752ac805903ecb832f437ab41bb6ce3

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

In Oncology

Citations in the corpus

Comprehensive review of targeted therapy for colorectal cancer (2020, result): “In this second-line-setting trial, a combination of ramucirumab and FOLFIRI significantly prolonged PFS (5.7 vs. 4.5 months; HR= 0.79, p < .0005) and OS (13.3 vs. 11.7 months, HR= 0.84, p= 0.022) compared with FOLFIRI-placebo.205 Similar to the findings with aflibercept, a phase II trial showed that”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer (2019, background): “FOLFIRI + BEV [190, 191] CAPIRI + BEV (see comment ⑤) [192] FOLFIRI + RAM [193] Fig.”
Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer (2012, neutral): “• FOLFIRI [62] + Bmab [85] ▪ FOLFIRI + Rmab [86] • IRIS (note 6) [87] + Bmab • IRI [88] + Bmab • FOLFIRI (or IRI) + Cmab/Pmab [88, 89]”
A standardised, generic, validated approach to stratify the magnitude of clinical benefit that can be anticipated from anti-cancer therapies: the European Society for Medical Oncology Magnitude of Clinical Benefit Scale (ESMO-MCBS). (2015, neutral): “97) 1 [114]”
ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. (2016, background): “In view of the inclusion criteria of the bevacizumab, aflibercept and ramucirumab trials [283, 287, 289], aflibercept and ramucirumab may be considered for the treatment of patients with RAS mutant or unclassified tumours, and EGFR inhibitors for patients with RAS wild-type disease, especially when ”
Ten years of anti-vascular endothelial growth factor therapy (2016, background): “Most recently (April 2015), ramucirumab received FDA approval for the treatment of patients with metastatic colorectal cancer that progressed during or after first-line treatment with bevacizumab (RAISE study), in combination with second-line FOLFIRI 145 , representing the fourth VEGFA pathway inhib”